Kairos Pharma, Ltd. (KAPA)

Market Cap	16.06M
Revenue (ttm)	n/a
Net Income (ttm)	-2.74M
Shares Out	12.85M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,124
Open	1.290
Previous Close	1.330
Day's Range	1.200 - 1.330
52-Week Range	0.851 - 4.000
Beta	n/a
Analysts	Strong Buy
Price Target	9.00 (+620.0%)
Earnings Date	Mar 4, 2025

About KAPA

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-ĸβ pathway, a can...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 16, 2024
• Employees: 3
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: KAPA
• Website: https://kairospharma.com

Analyst Forecast

According to one analyst, the rating for KAPA stock is "Strong Buy" and the 12-month stock price forecast is $9.0.

Price Target

$9.0

(620.00% upside)

Analyst Consensus: Strong Buy